Table 7.

The lesion predictive value of the Oxford Classification for nonresponse to RAS blockade in 294 IgAN patients by Cox regression

Pathologic lesionPatientsRisk of No Response to RAS Blockade
Univariate Hazard Ratio (95% CI)Multivariate Hazard Ratio (95% CI)
Mesangial hypercellularity score
    ≤0.5107referencereference
    >0.51871.88 (1.37 to 2.59)1.74 (1.25 to 2.43)
P<0.001P = 0.001
Segmental glomerulosclerosis
    absent55referencereference
    present2391.62 (1.09 to 2.40)1.17 (0.75 to 1.82)
P = 0.020.35
Tubular atrophy/interstitial fibrosis
    0 to 25%228referencereference
    26 to 50%391.31 (0.88 to 1.95)1.13 (0.75 to 1.71)
    >50%272.04 (1.31 to 3.92)1.84 (1.15 to 2.94)
P = 0.002P = 0.02
Extracapillary hypercellularity
    absent116referencereference
    present1781.38 (1.01 to 1.86)1.19 (0.85 to 1.65)
P = 0.040.43
Combination of pathologic lesions (M0/1T0/1/2)
    M0T096reference
    M1T0128P = 0.0081.66 (1.14 to 2.40)
    M0T180.340.98 (0.42 to 2.30)
    M1T131P = 0.021.81 (1.09 to 3.01)
    M1T226P<0.0012.81 (1.70 to 4.65)
Risk of No Remission to RAS Blockade
Clinical parameterUnivariateMultivariate
PatientsHazard Ratio (95% CI)Hazard Ratio (95% CI)
Proteinuria2941.11 (1.05 to 1.16)1.10 (1.04 to 1.16)
P<0.001P = 0.001
Proteinuria range
<1g/day85reference
1 to 1.99 g/day99P = 0.011.83 (1.14 to 2.94)
2 to 3.5 g/day63P<0.0012.40 (1.50 to 3.86)
>3.5 g/day47P<0.0012.80 (1.70 to 4.62)
  • M0, mesangial hypercellularity score <0.5; M1, mesangial hypercellularity score >0.5; T0, tubular atrophy/interstitial fibrosis range from 0 to 25%; T1, tubular atrophy/interstitial fibrosis range from 26 to 50%; T2, tubular atrophy/interstitial fibrosis >50%; CI, confidence interval; eGFR, estimated GFR; MAP, mean arterial pressure; RAS, renin angiotensin system.

  • a Endocapillary, arterial lesions, and eGFR as well as MAP were not associated with inefficiency to RAS blockades therapy in univariate analysis.

  • b Multivariate Model: multivariate with pathologic features, including mesangial hypercellularity segmental glomerulosclerosis tubular atrophy/interstitial fibrosis and extracapillary hypercellularity, and clinical features, including initial eGFR, MAP, and proteinuria.